1 Kahn SE, "The relative contributions of insulin resistance and betacell dysfunction to the pathophysiology of Type 2 diabetes" 46 : 3-19, 2003
2 Haffner SM, "The homeostasis model in the San Antonio heart study" 20 : 1087-1092, 1997
3 Kubo K, "The effect of maitake mushrooms on liver and serum lipids" 2 : 62-66, 1996
4 Huang ES, "The effect of interventions to prevent cardiovascular disease in patients with type 2 diabetes mellitus" 111 : 633-642, 2001
5 Kim MY, "Phenolic compound concentration and antioxidant activities of edible and medicinal mushrooms from Korea" 56 : 7265-7270, 2008
6 AOAC, "Official Methods of Analysis of AOAC Int. 17th ed. Method 934.01, 942.05, 976.05, 954.02, 962.09" Association of Official Analytical Chemists 2000
7 Seto SW, "Novel hypoglycemic effects of Ganoderma lucidum waterextract in obese/diabetic (+db/+db) mice" 16 : 426-436, 2009
8 American Diabetes Association, "Management of dyslipidemia in adults with diabetes (Position Statement)" 22 : 56-59, 1999
9 Manohar V, "Effects of a water soluble extract of maitake mushroom on circulating glucose/insulin concentrations in KK mice" 4 : 43-48, 2002
10 Bobek P, "Effect of oyster mushroom and isolated β-glucan on lipid peroxidation and on the activities of antioxidative enzymes in rats fed the cholesterol diet" 8 : 469-471, 1997
1 Kahn SE, "The relative contributions of insulin resistance and betacell dysfunction to the pathophysiology of Type 2 diabetes" 46 : 3-19, 2003
2 Haffner SM, "The homeostasis model in the San Antonio heart study" 20 : 1087-1092, 1997
3 Kubo K, "The effect of maitake mushrooms on liver and serum lipids" 2 : 62-66, 1996
4 Huang ES, "The effect of interventions to prevent cardiovascular disease in patients with type 2 diabetes mellitus" 111 : 633-642, 2001
5 Kim MY, "Phenolic compound concentration and antioxidant activities of edible and medicinal mushrooms from Korea" 56 : 7265-7270, 2008
6 AOAC, "Official Methods of Analysis of AOAC Int. 17th ed. Method 934.01, 942.05, 976.05, 954.02, 962.09" Association of Official Analytical Chemists 2000
7 Seto SW, "Novel hypoglycemic effects of Ganoderma lucidum waterextract in obese/diabetic (+db/+db) mice" 16 : 426-436, 2009
8 American Diabetes Association, "Management of dyslipidemia in adults with diabetes (Position Statement)" 22 : 56-59, 1999
9 Manohar V, "Effects of a water soluble extract of maitake mushroom on circulating glucose/insulin concentrations in KK mice" 4 : 43-48, 2002
10 Bobek P, "Effect of oyster mushroom and isolated β-glucan on lipid peroxidation and on the activities of antioxidative enzymes in rats fed the cholesterol diet" 8 : 469-471, 1997
11 Kang TS, "Effect of Pleurotus eryngii on the blood glucose and cholesterol in diabetic rats" 29 : 86-90, 2001
12 Mooradian AD, "Dyslipidemia in type 2 diabetes mellitus" 5 : 150-159, 2009
13 Gianturco S, "Apolipoprotein B48 or its apolipoprotein B100 equivalent mediates binding of triglyceride-rich lipoproteins to their unique human monocyte-macrophage receptor" 8 : 968-976, 1998
14 Mori K, "Antiatherosclerotic effect of the edible mushrooms Pleurotus eryngii (eringi), Grifola frondosa (maitake), and Hypsizygus marmoreus (bunashimeji) in apolipoprotein E-deficient mice" 28 : 335-342, 2008
15 Kubo K, "Anti-diabetic activity present in the fruit body of Grifola frondosa (maitake) I" 17 : 1106-1110, 1994
16 Schifreen RS, "Accuracy, precision, and stability in measurement of hemoglobin A1c by “high performance” cation-exchange chromatography" 26 : 466-472, 1980